Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
A-Z
> VZV vaccines and drugs R&D solutions 
Current updates as to where we stand with eliminating varicella zoster virus (VZV):
The first VZV vaccine, Zostavax, was developed by Merck and was approved for marketing in 2006.
Shingrix is a VZV subunit vaccine developed by GSK and was approved by the US FDA in October 2017. The improved efficacy and marketing of Shingrix, the Zostavax market share was quickly diminished and has been discontinued.
SKYZoster™ is a live vaccine was approved in South KMFDS in September 2017 based on results of clinical trials conducted in domestic and global institutions.
In 2023, the live attenuated herpes zoster vaccine developed by Changchun Baker Biotechnology Co., Ltd. obtained the biological products batch certificate from the National Medical Products Administration.
| Product type | Molecule | Cat. No. | Product Description |
|---|
Over 90% purity verified by SDS-PAGE;
The binding activity of the antigen and its antibody was verified by ELISA with a linear range of 0.1-4ng/mL;
The proteins are expressed in HEK293 cells, which makes sure the proteins'structure is closer to the natural conformation.
High precision: CV values of intra- and inter-assay precision are <10%;
High recovery rate: the recovery rate is within 80%-120%;
Provide kits for human and mouse sample detection, supporting the evaluation of humoral immunity in preclinical and early clinical stages.
High sensitivity: The sensitivity of the kit is over 39 pg/mL;
Wide detection range: The detection range of the kit is 39-1250pg/mL, which can meet the detection needs of different concentrations;
High precision: CV values of intra- and inter-assay precision are <10%.
High sensitivity and specificity, can accurately detect gE protein in samples;
Recombinant expression in HEK293 cells with good batch-to-batch stability;
Can be used for gE protein detection or as an antibody standard.
Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) at 1 μg/mL (100 μL/well) can bind Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) with a linear range of 0.02-1 ng/mL (QC tested).
The detection range of Cat. No. RAS-A102 is 39-1250pg/mL, and the sensitivity is 39pg/mL.
The LOQ for kit RAS-A102 is 78 pg/mL, and the LOD is 39 pg/mL.
Both the capture and detection antibodies used in RAS-A185 are monoclonal antibodies.
The RAS-A185 and RAS-A102 kits differ in sensitivity and colorimetric methods. The RAS-A185 uses HRP-Anti-Glycoprotein E (VZV) antibody for direct color development, while RAS-A102 employs Biotin-Anti-Glycoprotein E (VZV) antibody plus Streptavidin-HRP for color development. Both can be used for quantitative detection of VZV gE protein, but RAS-A102 has higher sensitivity, allowing you to choose the appropriate kit based on protein expression levels.
This web search service is supported by Google Inc.
